- Home
- FURY vs IKNA Comparison
FURY vs IKNA Comparison
Compare FURY & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- IKNA
- Stock Information
- Founded
- FURY 2008
- IKNA 2016
- Country
- FURY Canada
- IKNA United States
- Employees
- FURY N/A
- IKNA N/A
- Industry
- FURY Precious Metals
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- FURY Basic Materials
- IKNA Health Care
- Exchange
- FURY Nasdaq
- IKNA Nasdaq
- Market Cap
- FURY 60.5M
- IKNA 64.7M
- IPO Year
- FURY N/A
- IKNA 2021
- Fundamental
- Price
- FURY $0.40
- IKNA $1.28
- Analyst Decision
- FURY Strong Buy
- IKNA Buy
- Analyst Count
- FURY 1
- IKNA 2
- Target Price
- FURY $1.10
- IKNA $3.00
- AVG Volume (30 Days)
- FURY 133.2K
- IKNA 84.9K
- Earning Date
- FURY 05-13-2025
- IKNA 03-06-2025
- Dividend Yield
- FURY N/A
- IKNA N/A
- EPS Growth
- FURY N/A
- IKNA N/A
- EPS
- FURY N/A
- IKNA N/A
- Revenue
- FURY N/A
- IKNA N/A
- Revenue This Year
- FURY N/A
- IKNA N/A
- Revenue Next Year
- FURY N/A
- IKNA N/A
- P/E Ratio
- FURY N/A
- IKNA N/A
- Revenue Growth
- FURY N/A
- IKNA N/A
- 52 Week Low
- FURY $0.35
- IKNA $1.22
- 52 Week High
- FURY $0.59
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- FURY 49.92
- IKNA 39.30
- Support Level
- FURY $0.39
- IKNA $1.27
- Resistance Level
- FURY $0.42
- IKNA $1.43
- Average True Range (ATR)
- FURY 0.02
- IKNA 0.07
- MACD
- FURY -0.00
- IKNA -0.00
- Stochastic Oscillator
- FURY 25.00
- IKNA 18.60
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.